These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38803975)

  • 1. Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns.
    Petit PR; Touret F; Driouich JS; Cochin M; Luciani L; Bernadin O; Laprie C; Piorkowski G; Fraisse L; Sjö P; Mowbray CE; Escudié F; Scandale I; Chatelain E; de Lamballerie X; Solas C; Nougairède A
    Heliyon; 2024 May; 10(10):e30862. PubMed ID: 38803975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19).
    Pagliano P; Sellitto C; Ascione T; Scarpati G; Folliero V; Piazza O; Franci G; Filippelli A; Conti V
    Expert Opin Drug Discov; 2022 Dec; 17(12):1299-1311. PubMed ID: 36508255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment.
    Githaka JM
    Bioinform Biol Insights; 2022; 16():11779322221085077. PubMed ID: 35342288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review.
    Richmond DiBello J; Raziano VT; Liu X; Puenpatom A; Peebles K; Khan NF; Hill DD
    Infect Dis Ther; 2024 Jun; 13(6):1177-1198. PubMed ID: 38743192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
    Miranda JA; McKinzie PB; Dobrovolsky VN; Revollo JR
    Environ Mol Mutagen; 2022 Aug; 63(7):320-328. PubMed ID: 36181379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molnupiravir for the treatment of COVID-19.
    Santani BG; LeBlanc BW; Thakare RP
    Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
    Grimes SL; Choi YJ; Banerjee A; Small G; Anderson-Daniels J; Gribble J; Pruijssers AJ; Agostini ML; Abu-Shmais A; Lu X; Darst SA; Campbell E; Denison MR
    mBio; 2023 Aug; 14(4):e0106023. PubMed ID: 37338298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.
    Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel.
    Weil C; Bergroth T; Eisenberg A; Whiteside YO; Caraco Y; Tene L; Chodick G
    Epidemiologia (Basel); 2023 Aug; 4(3):309-321. PubMed ID: 37606468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.